COL2A1_HUMAN,K1408R,0.414,-,-,-
COL2A1_HUMAN,I1421M,0.555,Altered Metal binding (Pr = 0.27 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered Transmembrane protein (Pr = 0.17 | P = 9.3e-03); Altered Stability (Pr = 0.16 | P = 0.02); Loss of Catalytic site at E1420 (Pr = 0.11 | P = 0.03), None,-
COL2A1_HUMAN,T1432S,0.110,-,-,-
COL2A1_HUMAN,A1433T,0.364,-,-,-
COL2A1_HUMAN,I1462V,0.590,Altered Disordered interface (Pr = 0.41 | P = 3.9e-03); Altered Metal binding (Pr = 0.29 | P = 4.2e-03); Gain of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Gain of Allosteric site at D1464 (Pr = 0.28 | P = 3.6e-03); Loss of Catalytic site at D1464 (Pr = 0.26 | P = 3.8e-03); Altered Transmembrane protein (Pr = 0.25 | P = 1.5e-03), ELME000233|ELME000237|ELME000333,-
COL2A1_HUMAN,I1463T,0.689,Altered Stability (Pr = 0.60 | P = 9.8e-04); Altered Disordered interface (Pr = 0.40 | P = 4.1e-03); Loss of Catalytic site at D1464 (Pr = 0.34 | P = 8.9e-04); Altered Metal binding (Pr = 0.28 | P = 6.6e-03); Altered Ordered interface (Pr = 0.28 | P = 0.05); Gain of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Gain of Allosteric site at D1464 (Pr = 0.28 | P = 4.3e-03); Altered Transmembrane protein (Pr = 0.27 | P = 7.1e-04); Loss of Strand (Pr = 0.26 | P = 0.03), ELME000237|ELME000333,-
COL2A1_HUMAN,I1465F,0.885,Altered Transmembrane protein (Pr = 0.32 | P = 1.0e-04); Altered Disordered interface (Pr = 0.32 | P = 0.01); Altered Metal binding (Pr = 0.30 | P = 3.9e-03); Gain of Allosteric site at D1464 (Pr = 0.29 | P = 2.8e-03); Altered Ordered interface (Pr = 0.27 | P = 0.05); Gain of Catalytic site at D1464 (Pr = 0.26 | P = 4.0e-03), ELME000237,-
COL2A1_HUMAN,M1468V,0.518,Altered Disordered interface (Pr = 0.30 | P = 0.02); Altered Metal binding (Pr = 0.27 | P = 7.2e-03); Altered Transmembrane protein (Pr = 0.26 | P = 9.8e-04); Gain of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Loss of Catalytic site at D1464 (Pr = 0.26 | P = 4.5e-03); Loss of Allosteric site at D1464 (Pr = 0.21 | P = 0.04), None,-
COL2A1_HUMAN,P1473A,0.345,-,-,-
COL2A1_HUMAN,V1479A,0.723,Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Metal binding (Pr = 0.27 | P = 7.1e-03); Altered Transmembrane protein (Pr = 0.27 | P = 7.3e-04); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q1475 (Pr = 0.14 | P = 5.3e-03); Loss of Catalytic site at E1476 (Pr = 0.10 | P = 0.04), None,-
COL2A1_HUMAN,V1484A,0.727,Altered Metal binding (Pr = 0.25 | P = 0.03); Altered Transmembrane protein (Pr = 0.22 | P = 3.1e-03), None,-
COL2A1_HUMAN,G846E,0.945,Gain of Loop (Pr = 0.28 | P = 0.02); Loss of Methylation at K848 (Pr = 0.28 | P = 1.0e-03); Loss of Acetylation at K848 (Pr = 0.23 | P = 0.02); Loss of Ubiquitylation at K848 (Pr = 0.15 | P = 0.04), PS00008,-
COL2A1_HUMAN,G384S,0.945,Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Methylation at R383 (Pr = 0.26 | P = 1.8e-03); Gain of O-linked glycosylation at T380 (Pr = 0.11 | P = 0.05), ELME000053|ELME000136|ELME000159,-
COL2A1_HUMAN,G315V,0.970,Loss of B-factor (Pr = 0.33 | P = 2.7e-03); Altered Metal binding (Pr = 0.19 | P = 0.05), ELME000064|ELME000136|ELME000159|PS00006,-
COL2A1_HUMAN,G1101R,0.953,Loss of Loop (Pr = 0.29 | P = 0.01); Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Methylation at R1106 (Pr = 0.19 | P = 8.7e-03), ELME000006|ELME000085,-
COL2A1_HUMAN,G495E,0.961,Loss of Acetylation at K490 (Pr = 0.28 | P = 6.4e-03); Gain of SUMOylation at K490 (Pr = 0.27 | P = 4.9e-03); Loss of Methylation at K490 (Pr = 0.26 | P = 1.6e-03), ELME000117,-
COL2A1_HUMAN,G504A,0.943,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of Methylation at R509 (Pr = 0.12 | P = 0.02), ELME000155,-
COL2A1_HUMAN,G1086V,0.971,Loss of B-factor (Pr = 0.29 | P = 0.01); Gain of Acetylation at K1084 (Pr = 0.22 | P = 0.03); Loss of Methylation at K1084 (Pr = 0.21 | P = 5.0e-03); Loss of SUMOylation at K1084 (Pr = 0.20 | P = 0.03); Gain of Ubiquitylation at K1084 (Pr = 0.15 | P = 0.04), None,-
COL2A1_HUMAN,T1028M,0.429,-,-,-
COL2A1_HUMAN,G1110S,0.925,Gain of Phosphorylation at G1110 (Pr = 0.29 | P = 0.02); Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Methylation at R1106 (Pr = 0.18 | P = 9.0e-03), ELME000136|ELME000155|ELME000159,-
COL2A1_HUMAN,G711R,0.963,Gain of Methylation at R707 (Pr = 0.12 | P = 0.03), ELME000136|ELME000159|PS00005|PS00008,-
COL2A1_HUMAN,G282D,0.962,Loss of Acetylation at K287 (Pr = 0.26 | P = 9.1e-03); Loss of SUMOylation at K287 (Pr = 0.19 | P = 0.04); Loss of Methylation at K287 (Pr = 0.16 | P = 0.01), ELME000052|ELME000136|ELME000159|ELME000358,-
COL2A1_HUMAN,G684V,0.969,Loss of B-factor (Pr = 0.27 | P = 0.02); Loss of Methylation at K679 (Pr = 0.26 | P = 1.7e-03); Loss of Acetylation at K679 (Pr = 0.23 | P = 0.02); Gain of SUMOylation at K679 (Pr = 0.20 | P = 0.03), ELME000156,-
COL2A1_HUMAN,G966A,0.885,Loss of B-factor (Pr = 0.28 | P = 0.02); Altered Metal binding (Pr = 0.20 | P = 0.04), ELME000064|ELME000085|PS00006,-
COL2A1_HUMAN,G759D,0.966,Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of Acetylation at K764 (Pr = 0.27 | P = 8.3e-03); Loss of Methylation at K764 (Pr = 0.25 | P = 1.9e-03); Gain of Ubiquitylation at K764 (Pr = 0.20 | P = 9.4e-03), None,-
COL2A1_HUMAN,G369D,0.955,Gain of Loop (Pr = 0.29 | P = 0.01); Loss of Methylation at K374 (Pr = 0.27 | P = 1.2e-03); Gain of Ubiquitylation at K374 (Pr = 0.22 | P = 4.5e-03); Loss of Acetylation at K374 (Pr = 0.21 | P = 0.03), ELME000293|PS00008,-
COL2A1_HUMAN,G948D,0.966,Gain of Loop (Pr = 0.28 | P = 0.01); Loss of B-factor (Pr = 0.25 | P = 0.05), ELME000155,-
COL2A1_HUMAN,G369R,0.955,Loss of Loop (Pr = 0.29 | P = 0.01); Loss of Methylation at K374 (Pr = 0.28 | P = 8.9e-04); Gain of Acetylation at K374 (Pr = 0.25 | P = 0.01); Loss of Ubiquitylation at K374 (Pr = 0.21 | P = 5.6e-03), PS00008,-
COL2A1_HUMAN,G672C,0.949,Loss of B-factor (Pr = 0.36 | P = 6.0e-04); Gain of Loop (Pr = 0.27 | P = 0.02), None,-
COL2A1_HUMAN,R992G,0.875,Altered Disordered interface (Pr = 0.29 | P = 0.03); Gain of B-factor (Pr = 0.26 | P = 0.02); Gain of Methylation at R989 (Pr = 0.11 | P = 0.03), ELME000005|ELME000155|PS00008,-
COL2A1_HUMAN,G861D,0.959,Loss of Methylation at K857 (Pr = 0.28 | P = 1.0e-03); Loss of Acetylation at K857 (Pr = 0.25 | P = 0.01); Loss of SUMOylation at K857 (Pr = 0.23 | P = 0.02); Gain of Ubiquitylation at K857 (Pr = 0.19 | P = 0.01); Altered Metal binding (Pr = 0.11 | P = 0.04); Altered Transmembrane protein (Pr = 0.11 | P = 0.03), ELME000293,-
COL2A1_HUMAN,G873W,0.963,Loss of B-factor (Pr = 0.33 | P = 3.0e-03); Altered Disordered interface (Pr = 0.29 | P = 0.03); Gain of O-linked glycosylation at S869 (Pr = 0.16 | P = 0.03); Altered Metal binding (Pr = 0.11 | P = 0.04), ELME000155,-
COL2A1_HUMAN,G1158A,0.936,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of O-linked glycosylation at S1154 (Pr = 0.14 | P = 0.03); Gain of Methylation at R1163 (Pr = 0.13 | P = 0.02), ELME000155|ELME000239,-
COL2A1_HUMAN,G744S,0.922,Altered Metal binding (Pr = 0.10 | P = 0.04), ELME000136|ELME000159,-
COL2A1_HUMAN,G1140D,0.959,Loss of B-factor (Pr = 0.26 | P = 0.05), ELME000155,-
COL2A1_HUMAN,G813R,0.956,Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Methylation at R818 (Pr = 0.19 | P = 8.1e-03); Altered Metal binding (Pr = 0.11 | P = 0.04), ELME000006|ELME000085|ELME000239|PS00008,-
COL2A1_HUMAN,G1083D,0.965,Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Acetylation at K1084 (Pr = 0.22 | P = 0.03); Loss of Methylation at K1084 (Pr = 0.21 | P = 5.1e-03); Gain of SUMOylation at K1084 (Pr = 0.20 | P = 0.03); Gain of Ubiquitylation at K1084 (Pr = 0.17 | P = 0.03), PS00005,-
COL2A1_HUMAN,G522V,0.971,Altered Disordered interface (Pr = 0.30 | P = 0.02); Loss of Methylation at K527 (Pr = 0.23 | P = 3.3e-03); Loss of Acetylation at K527 (Pr = 0.22 | P = 0.03); Loss of SUMOylation at K527 (Pr = 0.19 | P = 0.04); Loss of Ubiquitylation at K527 (Pr = 0.16 | P = 0.04), None,-
COL2A1_HUMAN,G726D,0.970,Loss of Methylation at K731 (Pr = 0.27 | P = 1.3e-03); Gain of B-factor (Pr = 0.25 | P = 0.03); Loss of Acetylation at K731 (Pr = 0.23 | P = 0.02); Gain of Ubiquitylation at K731 (Pr = 0.19 | P = 0.01); Loss of SUMOylation at K731 (Pr = 0.18 | P = 0.05); Loss of O-linked glycosylation at T727 (Pr = 0.13 | P = 0.04); Altered Metal binding (Pr = 0.10 | P = 0.05), ELME000136|ELME000159|ELME000358|PS00008,-
COL2A1_HUMAN,G846R,0.951,Loss of Methylation at K848 (Pr = 0.30 | P = 5.9e-04); Loss of Loop (Pr = 0.27 | P = 0.04); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Acetylation at K848 (Pr = 0.26 | P = 9.7e-03); Loss of Ubiquitylation at K848 (Pr = 0.16 | P = 0.04), PS00008,-
COL2A1_HUMAN,G270R,0.966,Loss of B-factor (Pr = 0.30 | P = 0.01); Loss of Loop (Pr = 0.29 | P = 8.8e-03); Loss of Methylation at R266 (Pr = 0.19 | P = 7.9e-03), ELME000135|ELME000155,-
COL2A1_HUMAN,P986L,0.890,Altered Disordered interface (Pr = 0.35 | P = 0.01); Loss of Methylation at R989 (Pr = 0.10 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q988 (Pr = 0.05 | P = 0.04), ELME000155,-
COL2A1_HUMAN,G894E,0.964,Gain of O-linked glycosylation at T896 (Pr = 0.23 | P = 0.01), None,-
COL2A1_HUMAN,C57Y,0.941,Loss of Disulfide linkage at C57 (Pr = 0.26 | P = 3.8e-03), ELME000052|PS01208,-
COL2A1_HUMAN,R989C,0.827,Altered Disordered interface (Pr = 0.37 | P = 7.0e-03); Gain of Loop (Pr = 0.30 | P = 4.4e-03); Loss of Methylation at R989 (Pr = 0.11 | P = 0.03), None,-
COL2A1_HUMAN,G516S,0.965,Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of Methylation at R515 (Pr = 0.23 | P = 3.6e-03); Gain of N-linked glycosylation at N514 (Pr = 0.02 | P = 0.04), ELME000070|PS00001,-
COL2A1_HUMAN,G240C,0.957,Loss of B-factor (Pr = 0.29 | P = 0.01); Gain of Loop (Pr = 0.29 | P = 1.0e-02); Loss of Methylation at R242 (Pr = 0.16 | P = 0.01); Loss of O-linked glycosylation at S236 (Pr = 0.12 | P = 0.05), None,-
COL2A1_HUMAN,Y1399C,0.921,Altered Metal binding (Pr = 0.52 | P = 4.3e-03); Altered Ordered interface (Pr = 0.37 | P = 1.7e-03); Altered Transmembrane protein (Pr = 0.34 | P = 4.4e-05); Gain of Helix (Pr = 0.27 | P = 0.04); Gain of Disulfide linkage at Y1399 (Pr = 0.19 | P = 0.02), ELME000007|ELME000182|ELME000313,-
COL2A1_HUMAN,G207R,0.958,Loss of Loop (Pr = 0.27 | P = 0.03); Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of Methylation at R209 (Pr = 0.26 | P = 6.7e-04), ELME000006|ELME000012,-
COL2A1_HUMAN,G1062A,0.938,Altered Disordered interface (Pr = 0.28 | P = 0.04); Loss of Methylation at R1058 (Pr = 0.13 | P = 0.02), ELME000052|ELME000155,-
COL2A1_HUMAN,G753D,0.974,Loss of Methylation at R755 (Pr = 0.12 | P = 0.03), None,-
COL2A1_HUMAN,G474S,0.880,Loss of B-factor (Pr = 0.27 | P = 0.02); Gain of Loop (Pr = 0.26 | P = 0.05); Loss of Methylation at K470 (Pr = 0.23 | P = 3.8e-03); Loss of Acetylation at K470 (Pr = 0.20 | P = 0.04), ELME000136|ELME000155|ELME000159,-
COL2A1_HUMAN,R275C,0.867,Gain of Loop (Pr = 0.30 | P = 5.2e-03); Loss of Methylation at R275 (Pr = 0.15 | P = 0.02), ELME000005|ELME000155,-
COL2A1_HUMAN,G1041S,0.962,Loss of B-factor (Pr = 0.26 | P = 0.04); Altered Metal binding (Pr = 0.10 | P = 0.05), ELME000085|ELME000136|ELME000159|PS00008,-
COL2A1_HUMAN,G804A,0.947,Loss of B-factor (Pr = 0.26 | P = 0.03); Gain of SUMOylation at K803 (Pr = 0.26 | P = 6.5e-03); Loss of Acetylation at K803 (Pr = 0.25 | P = 0.01); Gain of Methylation at K803 (Pr = 0.24 | P = 1.0e-03); Gain of Ubiquitylation at K803 (Pr = 0.18 | P = 0.02); Altered Metal binding (Pr = 0.15 | P = 0.02), ELME000155,-
COL2A1_HUMAN,D1285Y,0.957,Altered Ordered interface (Pr = 0.37 | P = 2.3e-03); Altered Transmembrane protein (Pr = 0.23 | P = 2.2e-03); Loss of Disulfide linkage at C1283 (Pr = 0.14 | P = 0.04), ELME000106|ELME000120|ELME000146|ELME000182|ELME000220|PS00006,-
COL2A1_HUMAN,R550C,0.776,Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of ADP-ribosylation at R550 (Pr = 0.20 | P = 0.04); Loss of Methylation at R550 (Pr = 0.11 | P = 0.03), ELME000155,-
COL2A1_HUMAN,G1188R,0.960,Altered Disordered interface (Pr = 0.30 | P = 0.02); Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of Loop (Pr = 0.27 | P = 0.02); Gain of Methylation at R1190 (Pr = 0.24 | P = 1.3e-03); Loss of ADP-ribosylation at R1192 (Pr = 0.20 | P = 0.05), ELME000006|ELME000012|ELME000061|ELME000135,-
COL2A1_HUMAN,P458L,0.662,Altered Disordered interface (Pr = 0.35 | P = 0.01), ELME000052,-
COL2A1_HUMAN,G219R,0.969,Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of Methylation at G219 (Pr = 0.14 | P = 0.02), None,-
COL2A1_HUMAN,G462V,0.961,Altered Disordered interface (Pr = 0.27 | P = 0.05); Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Acetylation at K464 (Pr = 0.27 | P = 7.8e-03); Gain of SUMOylation at K464 (Pr = 0.27 | P = 4.9e-03); Loss of Methylation at K464 (Pr = 0.25 | P = 1.9e-03), ELME000237,-
COL2A1_HUMAN,G327D,0.971,Gain of Loop (Pr = 0.29 | P = 7.0e-03); Loss of Methylation at R326 (Pr = 0.23 | P = 3.9e-03), ELME000106,-
COL2A1_HUMAN,G1053V,0.969,Altered Disordered interface (Pr = 0.29 | P = 0.03); Loss of Acetylation at K1055 (Pr = 0.24 | P = 0.02); Loss of Methylation at K1055 (Pr = 0.23 | P = 3.7e-03); Loss of Ubiquitylation at K1055 (Pr = 0.19 | P = 0.01), None,-
COL2A1_HUMAN,G1143S,0.936,Gain of Phosphorylation at G1143 (Pr = 0.35 | P = 8.7e-03); Loss of B-factor (Pr = 0.27 | P = 0.02); Gain of Loop (Pr = 0.27 | P = 0.03), ELME000057|ELME000136|ELME000155|ELME000159,-
COL2A1_HUMAN,G687S,0.955,Gain of Loop (Pr = 0.27 | P = 0.04); Altered Metal binding (Pr = 0.11 | P = 0.04), None,-
COL2A1_HUMAN,R904C,0.715,Altered Disordered interface (Pr = 0.28 | P = 0.03); Gain of Loop (Pr = 0.27 | P = 0.03); Gain of B-factor (Pr = 0.25 | P = 0.04); Loss of ADP-ribosylation at R904 (Pr = 0.23 | P = 0.02); Loss of Methylation at R904 (Pr = 0.14 | P = 0.02), ELME000097|ELME000155|ELME000259|PS00008,-
COL2A1_HUMAN,G498V,0.969,Loss of B-factor (Pr = 0.30 | P = 9.5e-03); Gain of Loop (Pr = 0.26 | P = 0.04); Loss of Methylation at R494 (Pr = 0.16 | P = 0.01), ELME000233,-
COL2A1_HUMAN,G822D,0.967,Loss of Methylation at R818 (Pr = 0.19 | P = 7.6e-03), ELME000133,-
COL2A1_HUMAN,T638I,0.540,Altered Disordered interface (Pr = 0.45 | P = 1.8e-03); Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Acetylation at K634 (Pr = 0.25 | P = 0.01); Loss of Methylation at K634 (Pr = 0.22 | P = 4.3e-03); Gain of SUMOylation at K634 (Pr = 0.21 | P = 0.03); Loss of Ubiquitylation at K634 (Pr = 0.15 | P = 0.05), None,-
COL2A1_HUMAN,I2L,0.319,-,-,-
COL2A1_HUMAN,I2T,0.568,Altered Stability (Pr = 0.32 | P = 4.9e-03); Gain of N-terminal acetylation at M1 (Pr = 0.08 | P = 2.1e-03); Altered Signal peptide (Pr = 0.07 | P = 2.8e-03), ELME000355,-
COL2A1_HUMAN,R3L,0.482,-,-,-
COL2A1_HUMAN,G5R,0.731,Gain of Helix (Pr = 0.32 | P = 2.1e-03); Altered Signal peptide (Pr = 0.18 | P = 1.2e-03); Loss of N-terminal acetylation at M1 (Pr = 0.07 | P = 2.5e-03), ELME000012|ELME000051|ELME000233|PS00008,-
COL2A1_HUMAN,T9M,0.170,-,-,-
COL2A1_HUMAN,L10W,0.648,Altered Signal peptide (Pr = 0.25 | P = 5.7e-04), ELME000052|ELME000149|ELME000333|ELME000335|PS00008,-
COL2A1_HUMAN,V17I,0.119,-,-,-
COL2A1_HUMAN,V28I,0.086,-,-,-
COL2A1_HUMAN,Q29I,0.657,Loss of Pyrrolidone carboxylic acid at Q24 (Pr = 0.25 | P = 7.1e-04); Gain of Disulfide linkage at C34 (Pr = 0.21 | P = 0.02); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Altered Signal peptide (Pr = 0.01 | P = 5.1e-03), None,-
COL2A1_HUMAN,E30Q,0.178,-,-,-
COL2A1_HUMAN,A31E,0.386,-,-,-
COL2A1_HUMAN,N42K,0.349,-,-,-
COL2A1_HUMAN,W47R,0.864,Gain of Intrinsic disorder (Pr = 0.38 | P = 0.01); Gain of SUMOylation at K48 (Pr = 0.22 | P = 0.02); Altered Transmembrane protein (Pr = 0.16 | P = 0.01), ELME000102|ELME000155,-
COL2A1_HUMAN,T59D,0.503,Gain of Disulfide linkage at C57 (Pr = 0.20 | P = 0.02), ELME000052|ELME000147|PS01208,-
COL2A1_HUMAN,V62I,0.286,-,-,-
COL2A1_HUMAN,E79H,0.348,-,-,-
COL2A1_HUMAN,I88V,0.140,-,-,-
COL2A1_HUMAN,T91A,0.132,-,-,-
COL2A1_HUMAN,L93R,0.617,Gain of Intrinsic disorder (Pr = 0.32 | P = 0.03); Gain of O-linked glycosylation at S97 (Pr = 0.22 | P = 0.01); Gain of Proteolytic cleavage at L93 (Pr = 0.21 | P = 1.7e-03); Gain of ADP-ribosylation at L93 (Pr = 0.20 | P = 0.03), ELME000053|ELME000062|PS00005,-
COL2A1_HUMAN,S97G,0.404,-,-,-
COL2A1_HUMAN,G98S,0.849,Gain of O-linked glycosylation at T95 (Pr = 0.27 | P = 7.0e-03); Loss of B-factor (Pr = 0.25 | P = 0.05); Gain of Proteolytic cleavage at S97 (Pr = 0.21 | P = 1.7e-03); Loss of Methylation at K103 (Pr = 0.16 | P = 0.01), ELME000085|ELME000202|ELME000239,-
COL2A1_HUMAN,Q99N,0.241,-,-,-
COL2A1_HUMAN,P100S,0.400,-,-,-
COL2A1_HUMAN,P100W,0.700,Loss of Intrinsic disorder (Pr = 0.43 | P = 0.02); Loss of B-factor (Pr = 0.33 | P = 2.4e-03); Loss of O-linked glycosylation at T95 (Pr = 0.22 | P = 0.02); Gain of Proteolytic cleavage at A96 (Pr = 0.18 | P = 4.9e-03); Loss of Methylation at K103 (Pr = 0.17 | P = 0.01); Gain of Pyrrolidone carboxylic acid at Q105 (Pr = 0.08 | P = 0.02), None,-
COL2A1_HUMAN,G104L,0.956,Loss of B-factor (Pr = 0.32 | P = 3.7e-03); Gain of SUMOylation at K106 (Pr = 0.23 | P = 0.02); Gain of Acetylation at K106 (Pr = 0.22 | P = 0.03); Loss of Methylation at K106 (Pr = 0.18 | P = 9.9e-03); Loss of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), None,-
COL2A1_HUMAN,G104W,0.951,Loss of B-factor (Pr = 0.35 | P = 1.4e-03); Loss of SUMOylation at K106 (Pr = 0.22 | P = 0.02); Gain of Acetylation at K106 (Pr = 0.19 | P = 0.05); Loss of Methylation at K106 (Pr = 0.19 | P = 8.2e-03); Gain of Pyrrolidone carboxylic acid at Q105 (Pr = 0.08 | P = 0.02), None,-
COL2A1_HUMAN,Q105A,0.760,Loss of SUMOylation at K106 (Pr = 0.31 | P = 2.5e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of Acetylation at K106 (Pr = 0.20 | P = 0.04); Gain of Methylation at K106 (Pr = 0.19 | P = 6.3e-03); Loss of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), ELME000002|ELME000146,-
COL2A1_HUMAN,Q105E,0.616,Gain of B-factor (Pr = 0.29 | P = 4.8e-03); Gain of SUMOylation at K106 (Pr = 0.28 | P = 4.2e-03); Gain of Acetylation at K106 (Pr = 0.19 | P = 0.04); Gain of Methylation at K106 (Pr = 0.17 | P = 8.2e-03); Loss of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), ELME000002,-
COL2A1_HUMAN,K106P,0.808,Loss of SUMOylation at K106 (Pr = 0.32 | P = 2.3e-03); Gain of B-factor (Pr = 0.25 | P = 0.02); Loss of Acetylation at K106 (Pr = 0.23 | P = 0.02); Loss of Methylation at K106 (Pr = 0.21 | P = 5.3e-03); Gain of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), ELME000005|ELME000133|ELME000155,-
COL2A1_HUMAN,E108P,0.759,Gain of B-factor (Pr = 0.27 | P = 0.01); Loss of SUMOylation at K106 (Pr = 0.27 | P = 5.5e-03); Gain of Acetylation at K113 (Pr = 0.25 | P = 0.01); Gain of Methylation at K113 (Pr = 0.20 | P = 4.5e-03); Gain of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), None,-
COL2A1_HUMAN,G110S,0.848,Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Acetylation at K113 (Pr = 0.25 | P = 0.01); Gain of Phosphorylation at G110 (Pr = 0.24 | P = 0.04); Loss of SUMOylation at K106 (Pr = 0.22 | P = 0.02); Loss of Methylation at K113 (Pr = 0.19 | P = 8.1e-03); Gain of Proteolytic cleavage at D114 (Pr = 0.14 | P = 0.01); Loss of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), None,-
